2021
DOI: 10.1101/2021.11.22.21266512
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales

Abstract: ImportanceThe long-term effects of COVID-19 on the incidence of vascular diseases are unclear.ObjectiveTo quantify the association between time since diagnosis of COVID-19 and vascular disease, overall and by age, sex, ethnicity, and pre-existing disease.DesignCohort study based on population-wide linked electronic health records, with follow up from January 1st to December 7th 2020.Setting and participantsAdults registered with an NHS general practice in England or Wales and alive on January 1st 2020.Exposure… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
19
0
2

Year Published

2021
2021
2023
2023

Publication Types

Select...
3
2

Relationship

2
3

Authors

Journals

citations
Cited by 13 publications
(21 citation statements)
references
References 21 publications
0
19
0
2
Order By: Relevance
“…The phenotypes presented have already enabled other analyses with highly relevant public health policy implications, such as assessing the association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, and thrombocytopenic events, 15 assessing the use of antithrombotic medication on COVID-19 outcomes, 16 and studying the incidence of vascular diseases after COVID-19 infection. 17 Our study expands the literature in several key ways. To our knowledge, this is the largest study in terms of sample size and data fidelity to create and evaluate computable COVID-19 phenotypes by leveraging multiple sources of linked data at the national level spanning electronic health records, administrative health-care billing data, disease audits, and national registers.…”
Section: Discussionmentioning
confidence: 65%
“…The phenotypes presented have already enabled other analyses with highly relevant public health policy implications, such as assessing the association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, and thrombocytopenic events, 15 assessing the use of antithrombotic medication on COVID-19 outcomes, 16 and studying the incidence of vascular diseases after COVID-19 infection. 17 Our study expands the literature in several key ways. To our knowledge, this is the largest study in terms of sample size and data fidelity to create and evaluate computable COVID-19 phenotypes by leveraging multiple sources of linked data at the national level spanning electronic health records, administrative health-care billing data, disease audits, and national registers.…”
Section: Discussionmentioning
confidence: 65%
“…The incidence of venous and arterial events was higher in older people, and the risk of death after venous and arterial events was higher in people who had been diagnosed with or tested positive for COVID-19 than in people without COVID-19. In other studies, the cumulative excess risks up to 49 weeks after a COVID-19 diagnosis or positive test in linked primary and secondary care databases in England were 25 per 1000 for arterial and six per 1000 for venous thromboses, 6 and the cumulative risk of venous events in Sweden up to 30 days after a COVID-19 diagnosis or positive test was about two per 1000. 7…”
mentioning
confidence: 84%
“…However, it is unclear whether these general risk factors would also confound the estimates of effectiveness against COVID-19 related outcomes. COVID-19 vaccination, including booster vaccination, may protect against deaths that are not coded as due to COVID-19 by preventing harms of severe COVID-19, such as acute myocardial infarction and stroke(9,10). We are unable to compare our non-COVID-19 death results with other recent studies of booster effectiveness, because those studies did not report on non-COVD-19 death.…”
Section: Discussionmentioning
confidence: 99%